A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
NCT06732414 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2025-12-02
Summary
Background:
Allergic or sinus diseases can affect the skin, sinuses, airways, and other parts of the body. Examples include pollen and environmental allergies, food allergies, asthma, and eczema. To learn more about how to prevent and treat these diseases, researchers need to study data, blood, fluid, and tissue samples from people affected by them.
Objective:
To collect data, blood, fluid, and tissue samples from people with allergic or sinus diseases.
Eligibility:
People aged 3 to 100 years with allergic or sinus diseases.
Design:
Participants will have at least one clinic visit, and most participants will have a baseline visit, annual visit, and an end of study visit. The duration of the study is 1 to 3 years. During the first clinic visit, the following procedures will be done to collect data, blood, fluid, and tissue samples:
* Blood will be collected.
* Cells and fluid may be collected from the inside of the nose using a long swab, and a small piece of skin may be scraped from inside the nose.
* Skin cells will be collected by rubbing with a cotton swab.
* A urine sample will be collected.
* Allergy skin prick tests. Allergy-causing substances will be placed on the back or arm and the skin underneath gently scratched. If the participant is allergic to the substance, the skin may become red, itchy, and swollen locally ( at the site of the test).
* Lung function test. Participants will breathe into a machine that measures the air moving in and out of their lungs.
* If, as part of their routine care, participants are undergoing procedures such as having nasal polyps removed, skin tissue samples taken, or gastrointestinal biopsies, additional tissues may be collected for this study.
* Participants will complete online questionnaires regarding their symptoms, health, and life.
Participants may return for more visits for up to 3 years.
Conditions
- Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
lead NIH
Principal Investigators
-
Paneez Khoury, M.D. · National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility
- Min Age
- 3 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-28
- Primary Completion
- 2044-11-01
- Completion
- 2045-11-01
Countries
- United States
Study Locations
More Related Trials
-
Molecular Basis of Food Allergy
NCT01832324 ·Status: ENROLLING_BY_INVITATION
-
Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism
NCT00362999 ·Status: COMPLETED
-
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies
NCT00712920 ·Status: COMPLETED ·Phase: PHASE3
-
Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber
NCT03496103 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
NCT00258635 ·Status: COMPLETED ·Phase: PHASE2
-
Mechanisms of Allergen Immunotherapy
NCT00001910 ·Status: COMPLETED
-
Nasal Epithelium Gene Expression Profiling in Child Respiratory Allergic Disease
NCT00569361 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660517 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients
NCT02461797 ·Status: COMPLETED ·Phase: NA
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
NCT01160861 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
NCT01634958 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Allergic Rhinitis In Patients Who Also Have Asthma
NCT00296491 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Nasal Inflammatory Biomarkers
NCT03450031 ·Status: COMPLETED ·Phase: NA
-
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment
NCT01529229 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult
NCT06046391 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.
NCT06272409 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
NCT00813748 ·Status: COMPLETED
-
Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects
NCT03039101 ·Status: COMPLETED ·Phase: NA
-
Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites
NCT06427577 ·Status: RECRUITING ·Phase: NA
-
A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts
NCT01012752 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00719862 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety/Tolerability of Ragweed MATA MPL
NCT00423787 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00740792 ·Status: COMPLETED ·Phase: PHASE3
-
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis
NCT04286542 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies
NCT00660829 ·Status: COMPLETED ·Phase: PHASE3